Round Rock Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.54M Sell
18,032
-48
-0.3% -$10.3K 0.58% 22
2026
Q1
$3.93M Sell
18,080
-1,532
-8% -$340K 0.6% 24
2025
Q4
$4.48M Buy
19,612
+33
+0.2% +$7.52K 0.67% 21
2025
Q3
$4.53M Sell
19,579
-926
-5% -$189K 0.72% 22
2025
Q2
$3.81M Sell
20,505
-3
-0% -$558 0.66% 27
2025
Q1
$4.3M Buy
20,508
+210
+1% +$40.8K 0.8% 25
2024
Q4
$3.61M Sell
20,298
-415
-2% -$76.3K 0.74% 23
2024
Q3
$4.09M Sell
20,713
-48
-0.2% -$8.96K 0.96% 22
2024
Q2
$3.56M Buy
20,761
+783
+4% +$130K 0.87% 23
2024
Q1
$3.64M Sell
19,978
-3,580
-15% -$617K 0.87% 23
2023
Q4
$3.65M Buy
+23,558
New +$3.43M 0.92% 23

Other funds holding ABBV

Round Rock Advisors's ABBV Position: Q2 2026 in Review

Round Rock Advisors reduced its AbbVie (ABBV) stake by 0.27% in Q2 2026, selling an estimated $10.3K and leaving 18,032 shares worth $4.54M. The position accounts for 0.58% of the portfolio, ranked #22.

Round Rock Advisors first reported a position in ABBV in Q4 2023 and has held it in 11 quarters since. 4,194 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Round Rock Advisors held 18,032 shares of AbbVie worth $4.54M as of Q2 2026.
  • Round Rock Advisors sold 48 AbbVie shares in Q2 2026, an estimated $10.3K.
  • AbbVie made up 0.58% of Round Rock Advisors's portfolio in Q2 2026, its #22 holding.
  • Round Rock Advisors first reported a position in AbbVie in Q4 2023 and has held it in 11 quarters since.
  • 4,194 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Round Rock Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.